Latest News and Press Releases

Pharming today announced that the U.S. FDA has approved its sNDA for Joenja® as first treatment for children with APDS

Pharming Group to participate in investor conferences Sep. 14-15. H.C. Wainwright Growth Conference and Morgan Stanley Healthcare Conference in New York.

Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and...

Pharming to participate in Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2026.

Pharming Group to report second quarter and first half 2026 financial results on July 30, 2026, and host a conference call & webcast on the same day.

Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York. Thursday June 4, 2026 at 11:05 EDT/17:05 CEST.

Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.

Pharming announces the European Commission (EC) has granted Marketing Authorization for Joenja (leniolisib)